Palvella Therapeutics, Inc. (PVLA) Total Liabilities (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Total Liabilities for 12 consecutive years, with $107.9 million as the latest value for Q3 2024.
- On a quarterly basis, Total Liabilities rose 273.89% to $107.9 million in Q3 2024 year-over-year; TTM through Sep 2024 was $107.9 million, a 273.89% increase, with the full-year FY2023 number at $11.4 million, down 83.08% from a year prior.
- Total Liabilities was $107.9 million for Q3 2024 at Palvella Therapeutics, up from $105.9 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $110.3 million in Q3 2021 to a low of $11.4 million in Q4 2023.
- A 5-year average of $76.3 million and a median of $74.0 million in 2020 define the central range for Total Liabilities.
- Peak YoY movement for Total Liabilities: crashed 83.08% in 2023, then skyrocketed 273.89% in 2024.
- Palvella Therapeutics' Total Liabilities stood at $74.0 million in 2020, then surged by 38.96% to $102.8 million in 2021, then plummeted by 34.28% to $67.6 million in 2022, then plummeted by 83.08% to $11.4 million in 2023, then soared by 844.4% to $107.9 million in 2024.
- Per Business Quant, the three most recent readings for PVLA's Total Liabilities are $107.9 million (Q3 2024), $105.9 million (Q2 2024), and $106.4 million (Q1 2024).